Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Seitz

Showing results (211-220 of 219) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 219 results.
Nature|September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancerXiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
JCO Precision Oncology|March 16, 2022
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic ChemotherapyHiroko Masuda, Kenichi Harano, Sakiko Miura, et al.
American Journal of Medical Genetics|April 20, 1999
Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary dataD J Allingham-Hawkins, R Babul-Hirji, D Chitayat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast CancerMatteo Dugo, Chiun-Sheng Huang, Daniel Egle, et al.
NPJ Breast Cancer|June 21, 2023
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancerDavid B Page, Joanna Pucilowska, Brie Chun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trialM Dugo, C-S Huang, D Egle, et al.
Zeitschrift Fur Rheumatologie|July 4, 2018
[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs]C Fiehn, J Holle, C Iking-Konert, et al.
The Journal of Rheumatology|November 17, 2015
Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 PatientsPia Moinzadeh, Gabriela Riemekasten, Elise Siegert, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 7, 2012
Diagnostics of autoimmune bullous diseases in German dermatology departmentsNina van Beek, Diana Knuth-Rehr, Peter Altmeyer, et al.
Pageof 22

Showing results (211-220 of 219) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 219 results.
Nature|September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancerXiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
JCO Precision Oncology|March 16, 2022
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic ChemotherapyHiroko Masuda, Kenichi Harano, Sakiko Miura, et al.
American Journal of Medical Genetics|April 20, 1999
Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary dataD J Allingham-Hawkins, R Babul-Hirji, D Chitayat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast CancerMatteo Dugo, Chiun-Sheng Huang, Daniel Egle, et al.
NPJ Breast Cancer|June 21, 2023
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancerDavid B Page, Joanna Pucilowska, Brie Chun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trialM Dugo, C-S Huang, D Egle, et al.
Zeitschrift Fur Rheumatologie|July 4, 2018
[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs]C Fiehn, J Holle, C Iking-Konert, et al.
The Journal of Rheumatology|November 17, 2015
Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 PatientsPia Moinzadeh, Gabriela Riemekasten, Elise Siegert, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 7, 2012
Diagnostics of autoimmune bullous diseases in German dermatology departmentsNina van Beek, Diana Knuth-Rehr, Peter Altmeyer, et al.
Pageof 22